Harvard Bioscience (NASDAQ:HBIO) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a report issued on Monday. The firm set a “hold” rating on the medical instruments supplier’s stock.

Other research analysts also recently issued research reports about the company. Benchmark decreased their price objective on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a report on Monday, March 24th. KeyCorp reaffirmed a “sector weight” rating on shares of Harvard Bioscience in a research note on Wednesday, April 9th.

Harvard Bioscience Trading Down 3.3 %

HBIO stock opened at $0.38 on Monday. Harvard Bioscience has a one year low of $0.36 and a one year high of $4.08. The company has a market capitalization of $16.66 million, a PE ratio of -1.14 and a beta of 1.47. The company’s 50 day moving average price is $0.62 and its two-hundred day moving average price is $1.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06.

Hedge Funds Weigh In On Harvard Bioscience

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its stake in shares of Harvard Bioscience by 63.0% in the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 11,397 shares during the last quarter. Barclays PLC grew its position in shares of Harvard Bioscience by 304.4% in the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 44,150 shares during the last quarter. State Street Corp increased its stake in shares of Harvard Bioscience by 1.1% during the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after buying an additional 7,763 shares during the period. Geode Capital Management LLC raised its holdings in shares of Harvard Bioscience by 2.2% during the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock valued at $2,455,000 after acquiring an additional 19,972 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Harvard Bioscience by 11.1% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 200,032 shares of the medical instruments supplier’s stock valued at $422,000 after acquiring an additional 20,026 shares in the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.